Articles

We’re sorry, something doesn't seem to be working properly. Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.

We’re sorry, something doesn't seem to be working properly. Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.

We’re sorry, something doesn't seem to be working properly. Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.

Review series: New technologies

Written by renowned experts in the field, this collection of open access Review articles explores the use of RNA sequencing, cytometry, metabolomics and next-generation DNA sequencing in rheumatic disease.

Featured review: Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity

“Since 2002, one new agent has been approved by the US Food and Drug Administration for systemic lupus erythematosus (SLE). Experiences from the field conducting trials of all the agents tested during this period have provided valuable practical insights. These insights harnessed with basic methodological work on the minimal clinically important difference (MCID) should improve the efficiency and the clinical relevance of future trials.”

This review, by Choi et al., provides an update on methods to determine a clinically meaningful difference when conducting trials of new agents for SLE.

Advertisement

Logo

We’re sorry, something doesn't seem to be working properly. Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.

Advertisement